Volume 35, 12 March 2004 3/2004
 
  SPOT ON
 

Publication bias: studies with negative results often remain unpublished

 
  NEW ON THE MARKET
 

Nadifloxacin (NADIXA) for acne Alopecia: what's the benefit of external minoxidil for women

 
  THERAPIES FROM A CRITICAL VIEW POINT

Angiotensin converting enzyme inhibitors for patients with type 2 diabetes and albuminuria

 
  a-t READERS' QUESTIONS AND COMMENTS
 

Metformin: to be discontinued before surgery?
Carcinogenic potential of insulin analogues
Naltrexone and/or acamprosate in the treatment of alcohol dependence
Vasopressin (PITRESSSIN) off market
About the pricing of transdermal buprenorphine (TRANSTEC)

 
  IN BRIEF
 

Again: escitalopram is not better than citalopram
Calcium channel blocker amlodipine now as generics available
Herpes genitalis: long-term therapy reduces transmission rate
Autologous tumor cell vaccine for renal-cell carcinoma
Estrogen monotherapy increases risk for stroke
Manual versus powered toothbrushing
Humidifier cannot be recommended for doctor`s practice

 
  CURRENT ADR NETWORK REPORT
 

Hypersexuality under dopamine agonist Pramipexole

 
  SIDE EFFECTS
 

Dementia: olanzapine (ZYPREXA) increases mortality

 
© arznei-telegramm 3/2004